ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near Rochester, MN, USA:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Rochester, Minnesota, United States and 17 other locations

To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...

Enrolling
Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease
Drug: Placebo
Drug: RGLS8429

Phase 1

Regulus Therapeutics

Rochester, Minnesota, United States and 27 other locations

Locations recently updated

The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney ...

Enrolling
Autosomal Recessive Polycystic Kidney (ARPKD)
Drug: Tolvaptan Suspension
Drug: Tolvaptan Tablets

Phase 3

Otsuka
Otsuka

Rochester, Minnesota, United States and 27 other locations

This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease...

Active, not recruiting
Kidney Diseases
Diagnostic Test: Renasight
Natera
Natera

Rochester, Minnesota, United States and 30 other locations

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-...

Invitation-only
Kidney Diseases
Genetic Disease
Drug: DCR-PHXC

Phase 3

Dicerna Pharmaceuticals

Rochester, Minnesota, United States and 22 other locations

PLD (ADPLD) or associated with autosomal dominant polycystic kidney disease (ADPKD).In the Treatment Period of the trial, participa...

Active, not recruiting
Polycystic Liver Disease
Drug: Placebo
Drug: CAM2029

Phase 2, Phase 3

Camarus

Rochester, Minnesota, United States and 10 other locations

or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems rel...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Rochester, Minnesota, United States and 534 other locations

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants w...

Active, not recruiting
Primary Membranous Nephropathy
Drug: Tacrolimus
Drug: Methylprednisolone

Phase 3

Roche
Roche

Rochester, Minnesota, United States and 55 other locations

(LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease...

Active, not recruiting
IgA Nephropathy
Drug: Placebo
Drug: LNP023

Phase 3

Novartis
Novartis

Rochester, Minnesota, United States and 177 other locations

The aim of this study is to evaluate DCR-PHXC in participants with PH1 or PH2 and severe renal impairment, with or without dialysis.

Enrolling
End Stage Renal Disease
Primary Hyperoxaluria Type 2
Drug: DCR-PHXC

Phase 2

Dicerna Pharmaceuticals

Rochester, Minnesota, United States and 17 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems